B-Cancer	0	8	Melanoma	Melanoma	NN	B-NP
O	8	9	/	/	SYM	I-NP
B-Cancer	9	13	skin	skin	NN	I-NP
I-Cancer	14	20	cancer	cancer	NN	I-NP
O	21	30	screening	screening	NN	I-NP
O	31	38	clinics	clinic	NNS	I-NP
O	38	39	:	:	:	O
O	40	51	experiences	experience	NNS	B-NP
O	52	54	in	in	IN	B-PP
O	55	58	The	The	DT	B-NP
O	59	70	Netherlands	Netherlands	NNP	I-NP
O	70	71	.	.	.	O

O	72	74	In	In	IN	B-PP
O	75	79	1989	1989	CD	B-NP
O	80	83	and	and	CC	I-NP
O	84	88	1990	1990	CD	I-NP
O	89	91	we	we	PRP	B-NP
O	92	101	conducted	conduct	VBD	B-VP
O	102	105	two	two	CD	B-NP
O	106	110	free	free	JJ	I-NP
B-Cancer	111	119	melanoma	melanoma	NN	I-NP
O	119	120	/	/	SYM	B-NP
B-Organ	120	124	skin	skin	NN	I-NP
O	125	134	screening	screening	NN	I-NP
O	135	142	clinics	clinic	NNS	I-NP
O	143	145	in	in	IN	B-PP
O	146	149	Oss	Oss	NNP	B-NP
O	150	153	and	and	CC	I-NP
O	154	160	Arnhem	Arnhem	NNP	I-NP
O	161	163	in	in	IN	B-PP
O	164	167	the	the	DT	B-NP
O	168	179	Netherlands	Netherlands	NNP	I-NP
O	179	180	.	.	.	O

O	181	184	The	The	DT	B-NP
O	185	190	study	study	NN	I-NP
O	191	194	was	be	VBD	B-VP
O	195	202	carried	carry	VBN	I-VP
O	203	206	out	out	RP	B-PRT
O	207	212	along	along	IN	B-PP
O	213	216	the	the	DT	B-NP
O	217	222	lines	line	NNS	I-NP
O	223	225	of	of	IN	B-PP
O	226	229	the	the	DT	B-NP
O	230	236	recent	recent	JJ	I-NP
O	237	246	campaigns	campaign	NNS	I-NP
O	247	256	supported	support	VBN	B-VP
O	257	259	by	by	IN	B-PP
O	260	263	the	the	DT	B-NP
O	264	272	American	American	NNP	I-NP
O	273	280	Academy	Academy	NNP	I-NP
O	281	283	of	of	IN	B-PP
O	284	295	Dermatology	Dermatology	NNP	B-NP
O	295	296	.	.	.	O

O	297	299	Of	Of	IN	B-PP
O	300	304	2564	2564	CD	B-NP
O	305	312	persons	person	NNS	I-NP
O	313	321	screened	screen	VBD	B-VP
O	321	322	,	,	,	O
O	323	325	53	53	CD	B-NP
O	326	329	had	have	VBD	B-VP
B-Cancer	330	338	melanoma	melanoma	NN	B-NP
O	339	341	or	or	CC	I-NP
B-Cancer	342	353	nonmelanoma	nonmelanoma	NN	I-NP
I-Cancer	354	358	skin	skin	NN	I-NP
I-Cancer	359	365	cancer	cancer	NN	I-NP
O	366	367	(	(	(	O
O	367	368	2	2	CD	B-NP
O	368	369	.	.	.	O
O	369	370	1	1	CD	B-NP
O	370	371	%	%	NN	I-NP
O	371	372	)	)	)	O
O	372	373	.	.	.	O

O	374	384	Compliance	Compliance	NN	B-NP
O	385	389	with	with	IN	B-PP
O	390	396	follow	follow	VB	B-VP
O	396	397	-	-	HYPH	O
O	397	399	up	up	RP	B-PRT
O	400	403	for	for	IN	B-PP
O	404	411	persons	person	NNS	B-NP
O	412	416	with	with	IN	B-PP
O	417	426	suspected	suspect	VBN	B-NP
B-Cancer	427	435	melanoma	melanoma	NN	I-NP
O	435	436	/	/	SYM	O
B-Cancer	436	440	skin	skin	NN	B-NP
I-Cancer	441	447	cancer	cancer	NN	I-NP
O	448	451	was	be	VBD	B-VP
O	452	460	adequate	adequate	JJ	B-ADJP
O	461	462	(	(	(	O
O	462	464	93	93	CD	B-NP
O	465	467	of	of	IN	B-PP
O	468	471	103	103	CD	B-NP
O	471	472	;	;	:	O
O	473	475	90	90	CD	B-NP
O	475	476	.	.	.	O
O	476	477	3	3	CD	B-NP
O	477	478	%	%	NN	I-NP
O	478	479	)	)	)	O
O	479	480	.	.	.	O

